Hematologic Oncology | Specialty

Dr. Richardson Discusses the FDA Approval of Selinexor in Myeloma

July 3rd 2019

Paul Richardson, MD, clinical program leader, director of clinical research, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, RJ Corman Professor of Medicine, Harvard Medical School, discusses the FDA approval of selinexor in multiple myeloma.

Monitoring in CML Remains Imperative as TKI Cessation Rises to the Forefront of Care

July 3rd 2019

Vivian G. Oehler, MD, discusses the important aspects of TKI discontinuation and the patient factors that would warrant such an approach.

Expert Sorts Through Treatment Strategies in Follicular Lymphoma

July 2nd 2019

Chaitra S. Ujjani, MD, discusses the various therapeutic classes and agents that are showing the most promise in the field of follicular lymphoma.

Influx of Targeted Therapies Prompts Several Questions in AML Paradigm

July 2nd 2019

Mary-Elizabeth Percival, MD, discusses advances and challenges with targeted agents in acute myeloid leukemia and remaining questions in the field.

Dr. Fertrin on the FDA Approval of Avatrombopag in ITP

July 2nd 2019

Kleber Y. Fertrin, MD, PhD, assistant professor, University of Washington School of Medicine, Seattle Cancer Care Alliance, discusses the FDA approval of avatrombopag in immune thrombocytopenia (ITP).

Dr. Tiacci on Vemurafenib/Rituximab Combo in HCL

July 2nd 2019

Enrico Tiacci, MD, discusses safety and efficacy results of a trial evaluating the BRAF inhibitor vemurafenib combined with rituximab in hairy cell leukemia.

FDA Approves Avatrombopag in Chronic ITP

July 1st 2019

The FDA has approved a supplemental new drug application to expand the use of avatrombopag to include the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to prior therapy.

MRD Could Take Center Stage in Pediatric and Adult ALL Paradigms

June 27th 2019

Jerald P. Radich, MD, the methods that are used to measure minimal residual disease and the work being done to standardize its use in acute lymphoblastic leukemia.

Gilteritinib Helps Set New Pace in Acute Myeloid Leukemia

June 26th 2019

Alexander E. Perl, MD, discusses gilteritinib’s place in the acute myeloid leukemia landscape and its potential future in the frontline setting.

Dr. Shah on Results of ZUMA-3 Study for ALL

June 26th 2019

Bijal Shah, MD, discusses the results of the phase I/II ZUMA-3 study, which looked at using KTE-X19, an anti-CD19 CAR T-cell therapy, to treat patients with relapsed/refractory acute lymphoblastic leukemia.

FDA Lifts Partial Clinical Hold on Venetoclax Myeloma Trial

June 25th 2019

The FDA has lifted a partial clinical hold that was placed on the phase III CANOVA (M13-494; NCT03539744) trial, which is examining venetoclax in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma that harbors t(11;14), according to AbbVie, the company that co-develops the BCL-2 inhibitor with Roche.

New Approaches Are Shifting the Landscape in Immune Thrombocytopenia

June 24th 2019

During a recent OncLive Peer Exchange discussion, a trio of immune thrombocytopenia specialists review clinical trial data that led to approval of the second-line agents, talk about efforts to refine first-line treatment, and discuss how they approach therapy selection for refractory patients. Finally, they highlight emerging therapies for ITP and the need to expand the pipeline.

Nivolumab/Brentuximab Vedotin Combo Is Highly Active in Relapsed/Refractory PMBCL

June 21st 2019

Nearly three-fourths of patients with relapsed/refractory primary mediastinal large B-cell lymphoma responded to a combination of nivolumab (Opdivo) plus brentuximab vedotin (Adcetris).

Rapid Changes in Multiple Myeloma Provide a Windfall of Treatment Options

June 21st 2019

S. Vincent Rajkumar, MD, discusses the rapidly changing landscape for the treatment of multiple myeloma, the future of immunomodulatory drugs, and whether quadruplet regimens will become more frequent.

FDA Issues Complete Response Letter for Quizartinib in AML

June 21st 2019

The FDA has issued a complete response letter to Daiichi Sankyo informing the company that its new drug application would not be approved for quizartinib for the treatment of adult patients with relapsed/refractory FLT3-ITD–positive acute myeloid leukemia.

Optimal Upfront Lenalidomide/R-CHOP Use Remains Puzzle in DLBCL

June 20th 2019

Patients with activated B-cell-type diffuse large B-cell lymphoma with a poor prognosis may benefit from frontline treatment with lenalidomide plus standard R-CHOP, according to subgroup data from the phase III ROBUST trial presented at the 2019 International Conference on Malignant Lymphoma.

Dr. Davids on the Phase II CRC043 Trial for Patients With Richter's Transformation

June 19th 2019

Matthew S. Davids, MD, MMSc, associate director, Center for Lymphocytic Leukemia, physician, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses the use of the BCL‐2 inhibitor, venetoclax (Venclexta) with dose-adjusted infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (R-EPOCH) to treat patients with Richter

Maintenance Therapy Remains Challenging Strategy in DLBCL

June 19th 2019

Maintenance therapy with rituximab did not lead to an improvement in disease-free survival among patients who achieved complete remission following 4 cycles of R-CHOP.

Quizartinib Receives Japanese Approval in Relapsed/Refractory FLT3+ AML

June 18th 2019

The Ministry of Health, Labor and Welfare of Japan has approved quizartinib for the treatment of adult patients with relapsed/refractory FTL3-ITD–positive acute myeloid leukemia, as detected by an MHLW-approved assay.

HCL Management: Recommendations and Advice

June 18th 2019